Niraparib Approved in Europe for Ovarian Cancer

November 22, 2017 – The European Commission has approved niraparib as a maintenance therapy for women with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is indicated regardless of a patient’s BRCA mutation status, making it the only once-daily PARP 1/2 inhibitor approved in Europe that does not require biomarker testing … (leggi tutto)